Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Toronto

$150,000.00

Targeting GABA-A receptors to treat depression with nitrous oxide

FY 2023-24

Summary
Supervisor: Dr. Beverley Orser, University of Toronto Almost one in 20 people suffer from depression, and it has wide-ranging impacts on individuals, families, and society. Current treatments can take weeks to work and, unfortunately, do not work at all for many patients. Recently, a search for alternatives has led researchers to experiment with common anesthetics as new treatments for depression. Nitrous oxide (N2O) is an anesthetic gas that has been in use for 250 years. It is widely used during surgeries, for labouring women, and in dental offices, so its safety is well-established. Recently, clinical trials have found that brief N2O exposures cause immediate and long-lasting improvements in depression, with few side effects. However, how N2O treats depression is not yet understood. Our group specializes in research on a brain receptor called the gamma-aminobutyric acid type A receptor (GABAAR). Recent work has found that drugs which decrease GABAAR activity improve depression, and we believe this may underpin N2O's antidepressant effects. We hypothesize that N2O treats depression by reducing GABAAR activity, and that this effect will persist long after treatment. We will test our hypothesis by experimenting on cells from the brains of mice, treated with N2O. By measuring the activity of molecules inside the cells, and electrical signals on their surface, we hope to identify each step in how N2O works as an antidepressant. In addition to these cells, we will also perform experiments on mice which are conditioned to behave like depressed humans, and will study the effects that treatment with N2O has on their mood and behaviours. This work has the potential to define an important new antidepressant mechanism for N2O, one of the oldest and safest anesthetics used today. It may expand the use of N2O as a treatment for depressed patients, and help researchers to better understand depression itself so that other safe and effective treatments can be developed.
Program
Doctoral: Vanier Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
495719
Name
Brenna Connor
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Targeting GABA-A receptors to treat depression with nitrous oxide
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Behaviour; Cellular Neurobiology; Depression; Electrophysiology; Gabaa Receptors; Mice; Molecular Neurobiology; Nitrous Oxide; Tonic Inhibition
Abstract
Supervisor: Dr. Beverley Orser, University of Toronto Almost one in 20 people suffer from depression, and it has wide-ranging impacts on individuals, families, and society. Current treatments can take weeks to work and, unfortunately, do not work at all for many patients. Recently, a search for alternatives has led researchers to experiment with common anesthetics as new treatments for depression. Nitrous oxide (N2O) is an anesthetic gas that has been in use for 250 years. It is widely used during surgeries, for labouring women, and in dental offices, so its safety is well-established. Recently, clinical trials have found that brief N2O exposures cause immediate and long-lasting improvements in depression, with few side effects. However, how N2O treats depression is not yet understood. Our group specializes in research on a brain receptor called the gamma-aminobutyric acid type A receptor (GABAAR). Recent work has found that drugs which decrease GABAAR activity improve depression, and we believe this may underpin N2O's antidepressant effects. We hypothesize that N2O treats depression by reducing GABAAR activity, and that this effect will persist long after treatment. We will test our hypothesis by experimenting on cells from the brains of mice, treated with N2O. By measuring the activity of molecules inside the cells, and electrical signals on their surface, we hope to identify each step in how N2O works as an antidepressant. In addition to these cells, we will also perform experiments on mice which are conditioned to behave like depressed humans, and will study the effects that treatment with N2O has on their mood and behaviours. This work has the potential to define an important new antidepressant mechanism for N2O, one of the oldest and safest anesthetics used today. It may expand the use of N2O as a treatment for depressed patients, and help researchers to better understand depression itself so that other safe and effective treatments can be developed.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Brenna, Connor
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~